ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,598.66
0.33%
Dow Jones
44,561.64
0.01%
Gold vs US Dollar
2,873.41
1.11%
Brent Oil
75.085
-1.13%
Bitcoin
98,472.27
0.62%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Oncocyte Corporation (OCX)

  7. Oncocyte Corporation (OCX) News

Oncocyte (OCX)

Oncocyte Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OCX
DateTimeSourceHeadlineSymbolCompany
08/01/202521:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCXOncocyte Corporation
08/01/202513:30GlobeNewswire Inc.Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical OfficerNASDAQ:OCXOncocyte Corporation
06/01/202521:05GlobeNewswire Inc.Oncocyte Expands Market Opportunity for VitaGraft™ KidneyNASDAQ:OCXOncocyte Corporation
09/12/202421:05GlobeNewswire Inc.Oncocyte to Participate in “J.P. Morgan Week” and Host Investor MeetingsNASDAQ:OCXOncocyte Corporation
09/12/202413:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCXOncocyte Corporation
04/12/202421:15GlobeNewswire Inc.Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New StudyNASDAQ:OCXOncocyte Corporation
02/12/202421:05GlobeNewswire Inc.Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms NASDAQ:OCXOncocyte Corporation
12/11/202421:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCXOncocyte Corporation
12/11/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCXOncocyte Corporation
12/11/202421:05GlobeNewswire Inc.Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025NASDAQ:OCXOncocyte Corporation
06/11/202421:45GlobeNewswire Inc.Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12NASDAQ:OCXOncocyte Corporation
22/10/202420:12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OCXOncocyte Corporation
22/10/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OCXOncocyte Corporation
18/10/202420:55Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:OCXOncocyte Corporation
16/10/202421:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OCXOncocyte Corporation
16/10/202420:15GlobeNewswire Inc.Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los AngelesNASDAQ:OCXOncocyte Corporation
15/10/202420:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCXOncocyte Corporation
15/10/202420:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCXOncocyte Corporation
08/10/202420:05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:OCXOncocyte Corporation
08/10/202412:30GlobeNewswire Inc.Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical TrialNASDAQ:OCXOncocyte Corporation
04/10/202423:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCXOncocyte Corporation
03/10/202410:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCXOncocyte Corporation
02/10/202422:41GlobeNewswire Inc.Oncocyte Signs Leading Transplant Centers in US and GermanyNASDAQ:OCXOncocyte Corporation
02/10/202422:35GlobeNewswire Inc.Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesNASDAQ:OCXOncocyte Corporation
25/09/202420:09Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:OCXOncocyte Corporation
20/08/202413:00GlobeNewswire Inc.PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics TechnologyNASDAQ:OCXOncocyte Corporation
12/08/202420:10GlobeNewswire Inc.Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series StudyNASDAQ:OCXOncocyte Corporation
09/08/202410:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCXOncocyte Corporation
09/08/202410:25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OCXOncocyte Corporation
09/08/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OCXOncocyte Corporation
 Showing the most relevant articles for your search:NASDAQ:OCX

Your Recent History

BIT
TSWE
ETF
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads